GeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024. In the quarter to June 2026, revenue grew 11.4%, EPS fell 257.9%, free cash flow fell 585.6% and total debt rose 87.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow WGS
GeneDx Holdings Corp. (WGS) EV/Sales
As of 16 October 2026, GeneDx Holdings Corp. (WGS) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from −0.5× (March 2022) to 11.7× (November 2025); the current reading is higher than 66% of that period. That is below the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.4× | 30.13% |
| FY2024 | 6.5× | — |
| FY2023 | −0.1× | — |
| FY2022 | −0.1× | — |
| FY2021 | 0.4× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.4× | 7.85% |
| Mar 2026 | 4.1× | (51.47%) |
| Dec 2025 | 8.4× | 12.98% |
| Sep 2025 | 7.5× | 5.74% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CSTL Castle Biosciences, Inc. compare | 2.0× |
| OPK OPKO Health, Inc. compare | 2.0× |
| NEO NeoGenomics, Inc. compare | 3.4× |
| WGS GeneDx Holdings Corp. | 4.1× |
| VCYT Veracyte, Inc. compare | 5.3× |
| CDNA CareDx, Inc. compare | 6.4× |
| BLLN BillionToOne, Inc. compare | 10.3× |
| ADPT Adaptive Biotechnologies Corporation compare | 12.4× |
| PSNL Personalis, Inc. compare | 20.9× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)